Mineralocorticoid receptor antagonists (MRA) have an established prognostic benefit in patients with heart failure with reduced ejection fraction (HFrEF)(1). In the TOPCAT trial, spironolactone for heart failure with preserved ejection fraction (HFpEF) failed to meet statistical significance for the primary outcome of a composite of cardiovascular death, aborted cardiac arrest and heart failure hospitalisation(2). However, post hoc analysis of the TOPCAT revealed geographical variation in treatment response, suggesting potential clinical benefit of MRA in HFpEF. Finerenone, a novel nonsteroidal MRA, has been shown to have prognostic benefit in patients with chronic kidney disease and type 2 diabetes (T2DM). This editorial reviews the emerging evidence for its use in heart failure patients.
Author Sub-editor: Dr Hnin Zaw Dr Hnin Zaw is a cardiology registrar from the East of England Deanery with a specialist interest in electrophysiology and
Author Sub-editor: Dr Tha Htet Nyi Dr Tha Htet Nyi is a cardiology registrar in South London Deanery with subspecialty interests in multimodal cardiac imaging and
Author Sub-editor: Dr Chi Ho Fung Dr Chi Ho Fung graduated with Distinction from Imperial College School of Medicine in 2019 with an Intercalated Bachelor
Authors Heartbeat Sub-Editor: Alexandar Drampalou I am Dr.Alexandar Drampalou ,a cardiologist currently specializing in cardiac magnetic resonance (CMR) at Guy’s and St Thomas’ Hospital and
Authors Heartbeat Sub-Editor: Marina Zafeiri Dr Marina Zafeiri is an IMT3 in the Wessex deanery, with a strong interest in Cardiology. She graduated from Athens
Author Sub-editor: Dr Joshua Rowland Dr Joshua Rowland is a cardiology registrar working in the North West Deanery. He graduated from the University of Manchester
